Condition: Metastatic Castration-resistant Prostate Neoplasms · Metastatic Hormone-sensitive Prostate Cancer · Sponsor: Janssen Research & Development, LLC
The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of pasritamig and combination regimens in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of pasritamig with the combination regimens in Part 2 (dose expansion).
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| Florida Cancer Specialists | Sarasota, Florida, United States | Recruiting |
| Start Midwest | Grand Rapids, Michigan, United States | Recruiting |
| Washington University School Of Medicine | St Louis, Missouri, United States | Recruiting |
| Perlmutter Cancer Center at NYU Langone Brooklyn | Brooklyn, New York, United States | Recruiting |
| Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island | Mineola, New York, United States | Recruiting |
| NYU Langone Health | New York, New York, United States | Recruiting |
| Sidney Kimmel Cancer Center - Jefferson Health | Philadelphia, Pennsylvania, United States | Recruiting |
| Icon Cancer Centre Kurralta Park | Kurralta Park, Australia | Recruiting |
| Macquarie University | Macquarie University, Australia | Recruiting |
| Peter MacCallum Cancer Centre | Melbourne, Australia | Recruiting |
| Princess Alexandra Hospital | Woolloongabba, Australia | Recruiting |
| Hosp Univ Vall D Hebron | Barcelona, Spain | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05818683